DK0741577T3 - Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren - Google Patents

Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren

Info

Publication number
DK0741577T3
DK0741577T3 DK95910629T DK95910629T DK0741577T3 DK 0741577 T3 DK0741577 T3 DK 0741577T3 DK 95910629 T DK95910629 T DK 95910629T DK 95910629 T DK95910629 T DK 95910629T DK 0741577 T3 DK0741577 T3 DK 0741577T3
Authority
DK
Denmark
Prior art keywords
alpha
ifn
pct
liver
enterferon
Prior art date
Application number
DK95910629T
Other languages
English (en)
Inventor
Graham Russell Foster
Howard Christopher Thomas
Original Assignee
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404379A external-priority patent/GB9404379D0/en
Priority claimed from GB9420340A external-priority patent/GB9420340D0/en
Application filed by Imperial College filed Critical Imperial College
Application granted granted Critical
Publication of DK0741577T3 publication Critical patent/DK0741577T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK95910629T 1994-03-07 1995-03-07 Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren DK0741577T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9404379A GB9404379D0 (en) 1994-03-07 1994-03-07 Therapeutic improvement
GB9420340A GB9420340D0 (en) 1994-10-10 1994-10-10 Therapeutic improvement
PCT/GB1995/000488 WO1995024212A1 (en) 1994-03-07 1995-03-07 The use of interferon subtypes in the preparation of medicaments to treat viral infections

Publications (1)

Publication Number Publication Date
DK0741577T3 true DK0741577T3 (da) 2003-02-17

Family

ID=26304449

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95910629T DK0741577T3 (da) 1994-03-07 1995-03-07 Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren

Country Status (10)

Country Link
US (1) US6007805A (da)
EP (1) EP0741577B1 (da)
JP (1) JP4001379B2 (da)
AT (1) ATE227133T1 (da)
AU (1) AU1854695A (da)
DE (1) DE69528751T2 (da)
DK (1) DK0741577T3 (da)
ES (1) ES2186714T3 (da)
PT (1) PT741577E (da)
WO (1) WO1995024212A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US6436391B1 (en) * 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
IT1295657B1 (it) * 1997-11-04 1999-05-24 Alfa Wassermann Spa Oligopeptidi antiparalleli e oligopeptidi idrofobicamente complementari, matrici che li contengono e loro uso nella
ES2138565B1 (es) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
GB9818445D0 (en) * 1998-08-24 1998-10-21 Imp College Innovations Ltd Medicaments
US20020197235A1 (en) * 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1536839B1 (en) * 2001-11-09 2010-09-15 Intarcia Therapeutics, Inc Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2005046715A1 (ja) * 2003-11-12 2005-05-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 生理活性複合体
PT1711207E (pt) 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
MXPA06013412A (es) 2004-05-19 2007-01-23 Maxygen Inc Polipeptidos de interferon-alfa y conjugados.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
AU2006299901A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2272872A4 (en) 2008-03-21 2011-04-06 Hayashibara Biochem Lab MONOCLONAL ANTIBODIES SPECIFICALLY RECOGNIZING THE ALPHA 8 SUBTYPE OF THE HUMAN ALPHA INTERFERON AND ASSOCIATED MUTANT PROTEIN
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
GB201215873D0 (en) 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
ES2971046T3 (es) 2015-09-15 2024-06-03 Ilc Therapeutics Ltd Composiciones y métodos relacionados con el tratamiento de enfermedades
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH651308A5 (de) * 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
GB8303165D0 (en) * 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPH02197539A (ja) * 1989-01-26 1990-08-06 Tanaka Kikinzoku Kogyo Kk 装飾品用Ｃｏ含有貴金属材料
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
CA2129533A1 (en) * 1992-02-10 1993-08-19 Douglas Testa Improved alpha interferon composition and method for its production from human peripheral blood leukocytes

Also Published As

Publication number Publication date
ES2186714T3 (es) 2003-05-16
EP0741577B1 (en) 2002-11-06
EP0741577A1 (en) 1996-11-13
DE69528751T2 (de) 2003-07-10
JP4001379B2 (ja) 2007-10-31
JPH09509955A (ja) 1997-10-07
WO1995024212A1 (en) 1995-09-14
ATE227133T1 (de) 2002-11-15
AU1854695A (en) 1995-09-25
PT741577E (pt) 2003-03-31
US6007805A (en) 1999-12-28
DE69528751D1 (de) 2002-12-12

Similar Documents

Publication Publication Date Title
DK0741577T3 (da) Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
KR880010777A (ko) 바이러스 억제제와 결합한 dsRNA로 인간의 바이러스 감염을 치료하는 방법
ATE277612T1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
MY138860A (en) Hiv protease inhibitors.
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
HUP0002755A2 (hu) Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
DE60009146D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
TR200102024T2 (tr) Yeni tedavi.
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
FR2572286B1 (fr) Utilisation du 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide pour le traitement de maladies virales chez l'homme
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
EP1143981A4 (en) TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS
DK0671918T3 (da) Præparater indeholdende acyclovir-lignende forbindelser og 2-vinylsubstituerede nucleosidanaloge til behandling af virusinfektioner
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c